US 12,285,434 B2
Therapeutic, preventive, or improvement agent for inflammatory disease and allergic disease
Takahisa Murata, Tokyo (JP); Tatsuro Nakamura, Tokyo (JP); Taiki Hamabata, Tokyo (JP); and Kohei Ashina, Tokyo (JP)
Assigned to THE UNIVERSITY OF TOKYO, Tokyo (JP)
Appl. No. 17/414,559
Filed by The University of Tokyo, Tokyo (JP)
PCT Filed Dec. 17, 2019, PCT No. PCT/JP2019/049500
§ 371(c)(1), (2) Date Sep. 20, 2021,
PCT Pub. No. WO2020/130003, PCT Pub. Date Jun. 25, 2020.
Claims priority of application No. 2018-235139 (JP), filed on Dec. 17, 2018.
Prior Publication US 2022/0008435 A1, Jan. 13, 2022
Int. Cl. A61K 31/557 (2006.01); A23L 33/12 (2016.01); A61K 9/00 (2006.01); A61P 9/00 (2006.01); A61P 37/08 (2006.01)
CPC A61K 31/557 (2013.01) [A23L 33/12 (2016.08); A61K 9/0019 (2013.01); A61P 9/00 (2018.01); A61P 37/08 (2018.01)] 17 Claims
OG exemplary drawing
 
1. A method for treating, preventing, or improving an inflammatory disease, comprising administering an effective amount of (±) 5,6-dihydroxy-8Z,11Z,14Z,17Z-eicosatetraenoic acid (5,6-DiHETE) or a composition comprising the (±) 5,6-dihydroxy-8Z, 11Z, 14Z, 17Z-eicosatetraenoic acid (5,6-DiHETE) to a subject in need thereof.